Bilateral Basal Ganglia Hemorrhage in a Patient with Confirmed COVID-19


ABSTRACT
SUMMARY: Bilateral basal ganglia hemorrhage is exceedingly rare. To our knowledge, our patient is the first reported case of a confirmed coronavirus disease 2019 (COVID-19) patient who had bilateral basal ganglia hemorrhage. In the absence of other risk factors for bilateral deep cerebral involvement, we suspect that COVID-19 may be contributing to these rare pathologies. Most published data represent a correlation between COVID-19 and neurologic complications, and more research is still needed to prove causation.

ABBREVIATIONS: COVID-19 = coronavirus disease 2019; SARS-CoV-2 = Severe Acute Respiratory Syndrome coronavirus 2

COVID-19 is a highly communicable disease caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The highest viral load for SARS-CoV-2 can be found in the lungs, nasopharynx, and oropharynx, and lower levels are detected in the brain, kidneys, liver, and blood.1 Neurologic manifestations may occur in up to 50% of patients with coronavirus disease 2019 (COVID-19) and may include encephalopathy, anosmia, ageusia, headache, dizziness, seizure, stroke, increased intracranial pressure, SARS-CoV-2 meningitis, and necrotizing encephalitis.2-4 There have been cases of ischemic and hemorrhagic strokes in patients with COVID-19.5 Bilateral basal ganglia hemorrhages per se are exceedingly rare, with 1 study indicating less than 30 reported cases worldwide.6 Here we report a case of a patient with COVID-19 who presented with acute, bilateral basal ganglia hemorrhage.

CASE PRESENTATION
A woman in her 60s with past medical history of obstructive sleep apnea, gastrointestinal reflux, asthma, and migraines presented to our hospital with severe frontal headache, cough, and fatigue. Initial CT of the head was normal (Fig 1, left). Her sputum tested positive for SARS-CoV-2 RNA and she was sent home to quarantine. Two days later, she was found unresponsive at her home. She was normotensive. A CT of the head revealed bilateral basal ganglia acute parenchymal hematomas with surrounding edema and partial effacement of both lateral ventricles (Fig 1, right). The patient was intubated for airway protection.

CTA and CTV were negative for intracranial aneurysms, vascular malformations, vasospasm, or cerebral venous thrombosis. MR imaging revealed hyperintense lesions on T1, hypointense on T2, high signal on susceptibility-weighted imaging, and no diffusion restriction indicating acute basal ganglia hematomas (Fig 2). MRA and MRV revealed normal flow voids with no evidence of venous occlusion. The carboxyhemoglobin level was 2.7. Ethylene glycol testing was negative. The CSF was not tested for SARS-CoV-2 due to hospital pandemic restrictions. A urine drug screen was positive for prescribed amphetamines and marijuana.

Nine days after admission, the patient was extubated. A CT of the head revealed resolving hematomas. After extubation, the patient remained tachypneic, febrile, and required supplemental oxygen therapy. She developed leukocytosis, thrombocytosis, and lactic acidosis, concerning for either COVID-19 pulmonary manifestations and/or superimposed bacterial infection. Her C-reactive protein was 124.2; erythrocyte sedimentation rate, 99; D-dimer, 2.18; and fibrinogen, 436. The family decided to initiate comfort measures and the patient died 2 days later due to cardiorespiratory failure.

DISCUSSION
There have been other reports suggesting involvement of bilateral deep cerebral structures in COVID-19 (Table). There has been 1 previous case reported in the literature of bilateral basal ganglia involvement in a patient with presumed COVID-19 infection; however, that patient’s nasopharyngeal SARS-CoV-2 polymerase chain reaction was negative (Table).4 Poyiadji et al7 reported a case of a...
A woman with COVID-19 who was found to have hemorrhagic rim-enhancing lesions within the bilateral thalami and medial temporal lobes.

The basal ganglia and thalami are highly metabolically active regions, predisposing them to hypoxic-ischemic injury, toxic poisoning (carbon monoxide, methanol, cyanide), metabolic abnormalities (liver disease, Leigh disease, Wilson disease, hypoglycemia, and osmotic myelinolysis), and neurodegeneration. Focal flavivirus infection, toxoplasmosis, and primary CNS lymphoma can also attack the bilateral basal ganglia or thalami. The basal ganglia are supplied by small medial and lateral lenticulostriate arteries of the anterior and middle cerebral arteries, making them susceptible to hypertensive disease. However, basal ganglia hemorrhage in hypertensive disease is unilateral in most cases. Our patient was normotensive on presentation, making hypertensive hemorrhage less likely.

Because the venous drainage of the bilateral basal ganglia is into the great cerebral vein, bilateral basal ganglia hemorrhage could theoretically be explained by great cerebral vein thrombosis. There have been 6 reported cases of cerebral venous thrombosis in patients with COVID-19 in the literature. Although our patient’s MR venogram was negative, it is possible that the patient developed a cerebral venous thrombosis of her galenic venous system and had spontaneous lysis of her clot before imaging.

Traumatic bilateral basal ganglia hemorrhage has rarely been reported. Although our patient was found unconscious, she did not have any external signs of cranial trauma. Amphetamines in our patient’s urine may predispose to ischemia or hemorrhage, however her CTA and MRA were negative for vasospasm. The lesions did not exhibit restricted diffusion, as observed in several hypoxic-ischemic, toxic, or metabolic etiologies. Additionally, testing for carbon monoxide and ethylene glycol was negative.

It has been postulated that SARS-CoV-2 can be neurotropic via the transcripribiform route or

**FIG 1.** CT of the head obtained on day 1 of presentation (normal head CT, left). Two days later, a CT of the head was obtained because of worsening neurologic status (right). CT of the head revealed bilateral basal ganglia acute parenchymal hematomas measuring 2.7 cm × 1.9 cm × 1.4 cm (right) and 3.8 cm × 1.6 cm × 2.6 cm (left) with surrounding edema and partial effacement of bilateral lateral ventricles.

**FIG 2.** MR imaging of the brain revealing T1 hyperintense lesions (upper right) and high signal intensity on susceptibility-weighted imaging (SWAN, upper left). The lesions are hypointense on T2-weighted images (bottom right), exhibit surrounding edema on FLAIR images (bottom middle), and there is no diffusion restriction (DWI, bottom left).
Hemorrhagic involvement of bilateral deep cerebral structures in patients with COVID-19

<table>
<thead>
<tr>
<th></th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Our Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>50s</td>
<td>50s</td>
<td>60s</td>
</tr>
<tr>
<td>Sex</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>Anatomic location</td>
<td>Bilateral thalami, bilateral medial temporal lobes</td>
<td>Bilateral basal ganglia</td>
<td>Bilateral basal ganglia</td>
</tr>
<tr>
<td>SARS-CoV-2 PCR nasopharyngeal specimen</td>
<td>Positive</td>
<td>Negative</td>
<td>Positive</td>
</tr>
<tr>
<td>Medical history</td>
<td>Unknown</td>
<td>Diabetes, hypertension, lumbar fusion</td>
<td>Obstructive sleep apnea, gastrointestinal reflux, asthma, and migraines</td>
</tr>
<tr>
<td>Presenting symptom</td>
<td>Altered mental status</td>
<td>Loss of consciousness</td>
<td>Headache</td>
</tr>
<tr>
<td>COVID-19 symptoms</td>
<td>Cough, fever</td>
<td>Cough, fever</td>
<td>Cough, sore throat, fatigue</td>
</tr>
<tr>
<td>Presenting blood pressure</td>
<td>Unknown</td>
<td>150/100</td>
<td>134/70</td>
</tr>
<tr>
<td>Chest CT findings</td>
<td>Bilateral ground glass opacities</td>
<td>Bilateral ground glass opacities</td>
<td>Death</td>
</tr>
<tr>
<td>Outcome status</td>
<td>Recovered and discharged from the hospital</td>
<td>Not obtained</td>
<td>Not obtained</td>
</tr>
<tr>
<td>CSF</td>
<td>Negative for herpes simplex virus</td>
<td>Not obtained</td>
<td>Not obtained</td>
</tr>
</tbody>
</table>

Note:—PCR indicates polymerase chain reaction.

Disclosures: Farid Hamzei-Sichani—UNRELATED: Employment: University of Massachusetts Medical School.

REFERENCES